Navigation Links
Two are better than one

Cancer patients may one day benefit from treatment with mixtures of customized antibodies. In a study published recently in the Proceedings of the National Academy of Sciences (USA), a team of Weizmann Institute scientists have demonstrated how the right combination might form a web that destroys the cancer cell's communication network, ultimately demobilizing the cell.

Three decades of intensive cancer research led to the identification of a family of receptors, known as HER, that sit antenna-like on the outside of the cell wall and are implicated in certain types of cancer. A team of researchers under Prof. Yosef Yarden, Dean of the Weizmann Institute's Feinberg Graduate School and a professor in the Institute's Biological Regulation Department, had previously found that, under certain conditions, the HER2 receptor amplifies the growth signal received by the cell. Yarden and Prof. Michael Sela, former president of the Weizmann Institute of Science, and currently a professor in the Institute's Immunology Department, teamed up to create a strategy for the customization of antibodies that work independently to engage these cancer-specific receptors and shut down the attendant signaling network. The study was carried out in cooperation with researchers from Targeted Molecular Diagnostics, Westmont, IL, USA.

In experiments conducted in vitro and in lab mice, the researchers exposed the cancer cells to two different antibodies that link up to HER2 receptors. In a synergistic action, the antibodies were shown to cooperate rather than compete for distinctly different attachment points on the architecture of the receptors, resulting in the assembly of a large, springy molecular scaffolding between the receptor towers. The interlocking system grips and pulls the receptors towards each other until they collapse inward like overloaded laundry lines. The stressed receptors become engulfed by the cell, and thus cease signaling. In response, the cell halts growth and, when chemotherapy is used in combination with the immunotherapy, it dies.

According to Sela, the study sheds light on the synergy at work in the antibody-receptor therapy system. The results demonstrate that with the right combination of antibodies, receptor degradation is accelerated: it's more than three times as effective as a single antibody in inhibiting HER2 signaling.

"Understanding how HER receptor degradation works could enhance weak therapeutic efficacy, as well as provide ways to sensitize patients to overcome inherent or acquired resistance to cancer treatment," says Yarden.

Prof. Yosef Yarden's research is supported by the Y. Leon Benoziyo Institute for Molecular Medicine; the Dolfi and Lola Ebner Center for Biomedical Research; the J & R Center for Scientific Research; the Aharon Katzir-Katchalsky Center; the M.D. Moross Institute for Cancer Research; the Willner Family Center for Vascular Biology; the Batsheva De Rothschild Foundation; Dr. Marvin Klein, Farmington Hills, MI; Mr. & Mrs. Bram Laub, Belgium; and the Herbert J. Seligmann Charitable Trust. Prof. Yarden is the incumbent of the Harold and Zelda Goldenberg Professorial Chair in Molecular Cell Biology.

Prof. Michael Sela's research is supported by the Y. Leon Benoziyo Institute for Molecular Medicine, and the Dolfi and Lola Ebner Center for Biomedical Research. Prof. Sela is the incumbent of the W. Garfield Weston Professorial Chair of Immunology.


'"/>

Source:Weizmann Institute


Related biology news :

1. Chemists create Superbowl molecule; May lead to better health
2. Protein discovery could unlock the secret to better TB treatment
3. Signaling protein builds bigger, better bones in mice
4. Harnessing microbes, one by one, to build a better nanoworld
5. Discovery may lead to better Candidiasis drug
6. Insects, viruses could hold key for better human teamwork in disasters
7. Atmosphere may cleanse itself better than previously thought
8. Could better mangrove habitats have spared lives in the 2004 tsunami?
9. Muscle repair: Making a good system better, faster; implications for aging, disease
10. Plant genes identified that can form basis for crops better adapted to environmental conditions
11. Building a better mouse model of lung cancer: FHIT counts
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/23/2017)... Italy , May 23, 2017  Hunova, the first robotic gym ... trunk, has been officially launched in Genoa, Italy . ... Europe and the USA . The technology ... on the market by the IIT spin-off Movendo Technology thanks to a ... the Multimedia News Release, please click: ...
(Date:4/24/2017)... , April 24, 2017 ... and partner with  Identity Strategy Partners, LLP (IdSP) ... "With or without President Trump,s March 6, 2017 ... Terrorist Entry , refugee vetting can be instilled with ... resettlement. (Right now, all refugee applications are suspended ...
(Date:4/13/2017)... , April 13, 2017 UBM,s Advanced Design ... will feature emerging and evolving technology through its ... Summits will run alongside the expo portion of the ... panels and demonstrations focused on trending topics within 3D ... design and manufacturing event will take place June 13-15, 2017 ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... October 12, 2017 , ... ... analysis platform specifically designed for life science researchers to analyze and interpret ... Rosalind Franklin, who made a major contribution to the discovery of the ...
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for its ... 2018 in San Francisco, CA. The Summit brings together current and former FDA office ... directors and government officials from around the world to address key issues in device ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions ... over 5.5 million people each year. Especially those living in larger cities are affected ... based in one of the most pollution-affected countries globally - decided to take action. ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that ... Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los ...
Breaking Biology Technology: